Major shareholder in Pharmacolog exercises warrants of series TO3 for at least approximately SEK 0.54 million
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW.
The major shareholder Nolsterby Invest AB, that is controlled by the board members Erik Hedlund and Anders Hedlund exercises, warrants of series TO3 in Pharmacolog i Uppsala AB (“Pharmacolog” or the “Company”). The exercise period for the warrants of series TO3 began on February 9, 2024, and runs up to and including February 23, 2024.
The holders of warrants have the right for each owned warrant of series TO3 to subscribe to one (1) new series B share in Pharmacolog to a price of SEK 0.054 per share. Erik Hedlund, chairman of the board, and Anders Hedlund, board member, exercise 9,929,620 warrants of series TO3 through Nolsterby Invest AB, corresponding to 9,929,620 new series B shares to a value of approximately SEK 0.54 million. Additionally, Erik Hedlund and Anders Hedlund, through Nolsterby Invest AB, intend to exercise up to 9,000,000 warrants of series TO3, however, only to such extent that Nolsterby Invest AB’s share ownership does not exceed 29.9 per cent of the shares in the Company, corresponding to a subscription of up to 9,000,000 series B shares to an additional value of approximately SEK 0.49 million.
Advisors
Mangold Fondkommission AB is the financial advisor to Pharmacolog in connection with the exercise of the warrants. Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants.
For more information contact:
Lars Gusch, CEO
Email: lars.gusch@pharmacolog.com
Phone: +46 70-223 97 72
About Pharmacolog
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
The following trademarks are owned and protected by Pharmacolog i Uppsala AB: Pharmacolog™-logo, WasteLog™and Pharmacolog Dashboard™.
Further information regarding the company is available at https://perpetuamedical.se/.
The company’s Certified Adviser is Mangold Fondkommission AB.
Important information
The publication, announcement, or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions under law, and individuals in jurisdictions where this press release has been published or distributed should inform themselves about and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each respective jurisdiction. This press release does not constitute an offer to, or an invitation to, acquire or subscribe for any securities in Pharmacolog in any jurisdiction, neither from Pharmacolog nor from any other party.
This press release does not constitute an offer to sell or an invitation to acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States without registration or without applying an exemption from registration under the then-applicable U.S. Securities Act of 1933 (“Securities Act”), and may not be offered or sold in the United States without registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities mentioned herein in the United States or to conduct a public offering of such securities in the United States. The information in this press release may not be published, disclosed, copied, reproduced, or distributed, directly or indirectly, in whole or in part, in or to Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, the United States, Belarus, Russia, or any other jurisdiction where such publication, disclosure, or distribution of this information would be in violation of applicable rules or where such action is subject to legal restrictions or would require further registration or other measures than those required by Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities laws.